Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$33.15 USD
-1.52 (-4.38%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $32.95 -0.20 (-0.60%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CSTL 33.15 -1.52(-4.38%)
Will CSTL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
United Therapeutics Q3 Earnings & Sales Beat Estimates
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
Other News for CSTL
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To Expect
Castle Biosciences Inc (CSTL) Trading 3.24% Higher on Oct 29
Castle Biosciences price target raised to $42 from $35 at Canaccord
Castle Biosciences price target raised by $7 at Canaccord, here's why
Castle Biosciences to present new TissueCypher data at ACG 2024